Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis

被引:149
作者
Olsen, Trine [1 ]
Goll, Rasmus
Cui, Guanglin
Husebekk, Anne
Vonen, Barthold
Birketvedt, Grethe Stoa
Florholmen, Jon
机构
[1] Univ Tromso, Inst Clin Med, Lab Gastroenterol, NO-9037 Tromso, Norway
[2] Univ Hosp N Norway, Dept Immunol, Tromso, Norway
[3] Univ Hosp N Norway, Dept Colorectal Surg, Tromso, Norway
[4] Univ Hosp N Norway, Dept Med Gastroenterol, Tromso, Norway
关键词
D O I
10.1080/00365520701409035
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. The immune characterization of ulcerative colitis (UC) has been unclear and controversial. One possible explanation for the discrepancies between earlier cytokine studies in UC may be the fact that the patients included were on immunosuppressive therapy. Thus, the aim of this study was to determine the tumor necrosis factor-alpha (TNF-alpha) level and T(H)1/T(H)2 cytokine expression ( mRNA) profile in patients with untreated UC. Material and methods. Forty-four untreated UC patients, 10 untreated Crohn's disease ( CD) patients and 28 healthy controls were included in the study. Colon biopsies were processed for quantitative measurements of TNF-alpha, interleukin (IL)-10, IL-18, IL-4 and interferon-gamma (IFN-gamma) mRNA using real-time polymerase chain reaction (PCR). TNF-alpha expression in T-cell lymphocytes (CD3) and macrophages (CD68) were further characterized by immunohistochemistry (IHC). Results. Compared with the level in normal controls, the TNF-alpha mRNA level in UC patients was clearly increased, especially in patients with moderate to severe disease. The levels of TNF-alpha mRNA increased in proportion to the UC Disease Activity Index (UCDAI) score in UC patients. Differences were also observed between UC and controls for IFN-gamma IL-18, IL-4 and IL-10. Only minor quantitative differences in cytokines were observed between UC and CD, and they were more or less similar when comparing moderate to severe UC and CD. CD3+ lymphocytes and macrophages in lamina propria from CD and UC lesions showed increased intracellular staining of TNF-alpha. Conclusions. TNF-alpha is highly expressed in UC and correlates to the grade of inflammation. The sources of TNF-alpha were observed both in CD3+ lymphocytes and in macrophages. Cytokine expression (mRNA) profiles seem to be similar in patients with moderate to severe UC and CD.
引用
收藏
页码:1312 / 1320
页数:9
相关论文
共 45 条
[1]   Increased expression of tumor necrosis factor-α messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase [J].
Akazawa, A ;
Sakaida, I ;
Higaki, S ;
Kubo, Y ;
Uchida, K ;
Okita, K .
JOURNAL OF GASTROENTEROLOGY, 2002, 37 (05) :345-353
[2]   Inflammatory bowel disease: new insights into pathogenesis and treatment [J].
Ardizzone, S ;
Porro, GB .
JOURNAL OF INTERNAL MEDICINE, 2002, 252 (06) :475-496
[3]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P469
[4]   The immunological and genetic basis of inflammatory bowel disease [J].
Bouma, G ;
Strober, W .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (07) :521-533
[5]   AUTOIMMUNITY AND ULCERATIVE-COLITIS - CAN 2 ENIGMAS MAKE SENSE TOGETHER [J].
BRANDTZAEG, P .
GASTROENTEROLOGY, 1995, 109 (01) :307-312
[6]  
Brandtzaeg P, 2006, ADV EXP MED BIOL, V579, P149
[7]  
BRUIN KF, 1995, EUR J GASTROEN HEPAT, V7, P791
[8]   The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria [J].
Carlsen, Hege S. ;
Yamanaka, Takeshi ;
Scott, Helge ;
Rugtveit, Jarle ;
Brandtzaeg, Per .
INFLAMMATORY BOWEL DISEASES, 2006, 12 (11) :1013-1024
[9]   Improvement of real-time polymerase chain reaction for quantifying TNF-α mRNA expression in inflamed colorectal mucosa:: An approach to optimize procedures for clinical use [J].
Cui, G. ;
Olsen, T. ;
Christiansen, I. ;
Vonen, B. ;
Florholmen, J. ;
Goll, R. .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2006, 66 (03) :249-259
[10]  
CUI G, 2006, CANC IMMUNOL IMMUNOT